Document is current
Any future updates will be listed below
-
Authors
Leisman, Daniel E. https://orcid.org/0000-0001-9670-9425
Handisides, Damian R.
Chawla, Lakhmir S.
Albertson, Timothy E.
Busse, Laurence W.
Boldt, David W.
Deane, Adam M.
Gong, Michelle N.
Ham, Kealy R.
Khanna, Ashish K.
Ostermann, Marlies
McCurdy, Michael T.
Thompson, B. Taylor
Tumlin, James S.
Adams, Christopher D.
Hodges, Tony N.
Bellomo, Rinaldo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02338843 at ClinicalTrials.govDocuments that mention this clinical trial
An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock
https://doi.org/10.1186/s13054-025-05311-z
FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock
https://doi.org/10.1007/s40256-018-0297-9
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
https://doi.org/10.1186/s13054-023-04446-1
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
https://doi.org/10.1186/s13613-023-01227-5
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock
Journal Title: Annals of Intensive Care
CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-023-01227-5
Content Type: article
Copyright: Copyright © 2023 The Author(s) 2023. Published by Elsevier Masson SAS
